Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance

Also Vital For Partners Almirall

 
• By Andrew McConaghie
  
Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly is also awaiting FDA judgement on its JAK inhibitor Olumiant in atopic dermatitis, a fast expanding market for biologics.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D